One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the ...

Pfizer posted a slight revenue decline of 1.16% while absorbing a massive COVID hangover and betting billions on obesity drugs it does not yet own commercially. READ: The analyst who called NVIDIA in ...

Pfizer CEO Albert Bourla speaks shakes hands with U.S. President Donald Trump in a White House event on Tuesday. President Trump and Pfizer announced a deal to cut drug pricing yesterday. And it looks ...

Johnson & Johnson is a global leader in the pharmaceutical and medical device industries. Its key products include ...

By Maggie Fick, Bhanvi Satija and Patricia Weiss LONDON/FRANKFURT, June 10 (Reuters) - Pfizer is reviewing the timing and ...

Vertex Pharmaceuticals announced the FDA has accepted its biologics license application submission for povetacicept, an ...

Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the ...

US pharmaceutical giant Pfizer has pulled out of a meeting with German Chancellor Friedrich Merz over plans to reform the ...